Acceler8 Clinical Research Ltd 13949356 false 2022-04-01 2023-03-31 2023-03-31 The principal activity of the company is that of scientific activities Digita Accounts Production Advanced 6.30.9574.0 true 13949356 2022-04-01 2023-03-31 13949356 2023-03-31 13949356 bus:Original 2023-03-31 13949356 core:CurrentFinancialInstruments core:WithinOneYear 2023-03-31 13949356 bus:Micro-entities 2022-04-01 2023-03-31 13949356 bus:AuditExemptWithAccountantsReport 2022-04-01 2023-03-31 13949356 bus:FullAccounts 2022-04-01 2023-03-31 13949356 bus:SmallCompaniesRegimeForAccounts 2022-04-01 2023-03-31 13949356 bus:RegisteredOffice 2022-04-01 2023-03-31 13949356 bus:Director1 2022-04-01 2023-03-31 13949356 bus:Director2 2022-04-01 2023-03-31 13949356 bus:PrivateLimitedCompanyLtd 2022-04-01 2023-03-31 13949356 countries:AllCountries 2022-04-01 2023-03-31 iso4217:GBP xbrli:pure

Registration number: 13949356

Acceler8 Clinical Research Ltd

Unaudited Filleted Financial Statements

for the Year Ended 31 March 2023

 

Acceler8 Clinical Research Ltd

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

2

 

Acceler8 Clinical Research Ltd

Company Information

Directors

Mrs Kerri Clare Campbell

Mr Ewan James Campbell

Registered office

Booths Hall
Suite M3
Chelford Road
Knutsford
Cheshire
WA16 8GS

 

Acceler8 Clinical Research Ltd

(Registration number: 13949356)
Balance Sheet as at 31 March 2023

2023
£

Fixed assets

101,184

Current assets

37,734

Prepayments and accrued income

209

Creditors: Amounts falling due within one year

(117,758)

Net current liabilities

(79,815)

Total assets less current liabilities

21,369

Accruals and deferred income

(12,260)

 

9,109

Capital and reserves

9,109

1

General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
Booths Hall
Suite M3
Chelford Road
Knutsford
Cheshire
WA16 8GS
United Kingdom

These financial statements were authorised for issue by the Board on 1 December 2023.

Basis of preparation

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

2

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 3.

For the financial year ending 31 March 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

 

Acceler8 Clinical Research Ltd

(Registration number: 13949356)
Balance Sheet as at 31 March 2023

These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 1 December 2023 and signed on its behalf by:
 

.........................................
Mrs Kerri Clare Campbell
Director

.........................................
Mr Ewan James Campbell
Director